¼¼°èÀÇ ÀçÅà ÇコÄÉ¾î ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ÄÄÆ÷³ÍÆ®º°, ÀûÀÀÁõº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Home Healthcare Market Size, Share & Trends Analysis Report By Component (Equipment, Services), By Indication (Neurological & Mental Disorders, Cardiovascular Disorder & Hypertension), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1751494
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 220 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
ÀçÅà ÇコÄÉ¾î ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ º¸°í¼¿¡ µû¸£¸é, ¼¼°è Ȩ ÇコÄÉ¾î ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 7,477¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â 10.21%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÀçÅÃÄ¡·á ±â°üÀÌ Á¦°øÇÏ´Â ºñ¿ë È¿À²¼º, ȯÀÚ °á°ú °³¼± ¹× ÆíÀǼº¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ Áõ°¡¿Í ¾ËÃ÷ÇÏÀ̸Ӻ´, Ä¡¸Å, Á¤Çü¿Ü°ú Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2019³â 6¿ù¿¡ ¾÷µ¥ÀÌÆ®µÈ Àα¸¹®Á¦¿¬±¸¼ÒÀÇ ÀÚ·á¿¡ µû¸£¸é 65¼¼ ÀÌ»ó ³ëÀÎ Àα¸´Â 2018³â 5,200¸¸ ¸íÀ¸·Î 2060³â±îÁö µÎ ¹è·Î Áõ°¡ÇÏ¿© 9,500¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO) Åë°è¿¡ µû¸£¸é Àü ¼¼°è¿¡´Â ¾à 5,000¸¸ ¸íÀÇ Ä¡¸Å ȯÀÚ°¡ ÀÖÀ¸¸ç ¸Å³â 1,000¸¸ ¸íÀÌ »õ·Ó°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¼ýÀÚ´Â 2030³â¿¡´Â 8,200¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º´¿ø ¹× ±âŸ ÀÇ·á ½Ã¼³À» ¼³¸³Çϰí À¯ÁöÇÏ´Â °ÍÀº ÀÚº» Áý¾àÀûÀÎ ³ë·ÂÀÔ´Ï´Ù. µû¶ó¼ ÇコÄÉ¾î ¼Ö·ç¼Ç Á¦°ø¾÷üµéÀº ±âȸ¸¦ ÃÖ´ëÇÑ È°¿ëÇÏ°í ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ ±Þ¼ºÀåÇÏ´Â ½ÃÀå¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼´Â ÀçÅà º´¿ø ¸ðµ¨ÀÌ ±âŸ ±¹°¡¿¡ ºñÇØ ´ú º¸±ÞµÇ¾î ÀÖÁö¸¸, Áö³ 10³â°£ ÁÖ¸ñÇÒ ¸¸ÇÑ ¸î °¡Áö ³ë·ÂÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Á¸½º ȩŲ½º, ¸Ó½¬Çʵå Ŭ¸®´Ð Çコ ½Ã½ºÅÛ, 2016³â¿¡ PE°¡ Áö¿øÇÏ´Â ÄÜÅ×»ç¿Í Á¦ÈÞÇÑ ¸¶¿îÆ® ½Ã³ªÀÌÀÇ ÇÁ·Î±×·¥ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À̵é Á¶Á÷Àº Áö¿ªÀû ÀÔÁö¸¦ È®´ëÇϱâ À§ÇØ M&A¸¦ Àû±ØÀûÀ¸·Î Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¾ÆÆú·Î ȨÄɾî(Apollo Homecare)¿Í ¸Æ½º(Max&Home)¿Í °°Àº º´¿øµéÀÌ ÀεµÀÇ ÀçÅà ÄÉ¾î »ê¾÷¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Burman Àϰ¡(DaburÀÇ ¹ß±âÀÎ)¿Í ¿µ±¹¿¡ ±â¹ÝÀ» µÐ Healthcare at Home, ¹Ì±¹¿¡ ±â¹ÝÀ» µÐ India Home Healthcare¿Í Bayada Home Healthcare µî ÇÕÀÛȸ»ç¸¦ ¼³¸³ÇÑ °÷µµ ÀÖ½À´Ï´Ù.
Äڷγª19 »çŰ¡ Áö¼ÓµÊ¿¡ µû¶ó ÀçÅà °£È£ ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä´Â ´çºÐ°£ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºñ½º´Â º´¿ø ¼ºñ½º¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ¾ÈÀüÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. º´¿ø, ºñ°ø½Ä ÀÇ·á ¹× ±âŸ ÀÇ·á ½Ã¼³À» Æ÷ÇÔÇÑ ¿ÜºÎ ´ëüǰÀÇ À§ÇùÀº Á¦ÇÑÀûÀÌÁö¸¸, ´ëºÎºÐ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ Á¦ÇÑÀûÀÔ´Ï´Ù. µû¶ó¼ ÀÌ ½ÃÀåÀÇ ´ëüǰ À§ÇùÀº ¿¹Ãø ±â°£ µ¿¾È ¿Ï¸¸ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Ȩ ÇコÄÉ¾î ½ÃÀå º¸°í¼ÀÇ ÁÖ¿ä ³»¿ë
- ±¸¼º ¿ä¼Òº°·Î´Â ¼ºñ½º ºÎ¹®ÀÌ 2024³â 84.1%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- ÀûÀÀÁõº°·Î´Â ½Å°æ ¹× Á¤½ÅÁúȯ ºÎ¹®ÀÌ 2024³â 16.75%·Î °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ÀÌ´Â Áúº´ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
- ºÏ¹Ì Ȩ ÇコÄÉ¾î ½ÃÀåÀº 2024³â 42.47% ÀÌ»óÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ¼¼°è ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èº¸
- »óÀ§ ½ÃÀå ºÐ¼®
- º¸Á¶ ½ÃÀå ºÐ¼®
- ÀçÅà ÇコÄÉ¾î ½ÃÀå - ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ºñÁî´Ï½º ȯ°æ Åø ºÐ¼® : ÀçÅà ÇコÄÉ¾î ½ÃÀå
- PorterÀÇ Five Forces ºÐ¼®
- PESTLE ºÐ¼®
Á¦4Àå ÀçÅà ÇコÄÉ¾î ½ÃÀå : ÄÄÆ÷³ÍÆ®º°, ÃßÁ¤, µ¿Ç⠺м®
- ÀçÅà ÇコÄÉ¾î ½ÃÀå, ÄÄÆ÷³ÍÆ®º° ÁÖ¿ä Æ÷ÀÎÆ®
- ÀçÅà ÇコÄÉ¾î ½ÃÀå : ÄÄÆ÷³ÍÆ® µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
- ¼ºñ½º
- ÷´Ü ÀçÅà ÇコÄɾî
- ÀçÅà ÇコÄɾî
- Àåºñ
Á¦5Àå ÀçÅà ÇコÄÉ¾î ½ÃÀå : ÀûÀÀÁõº°, ÃßÁ¤, µ¿Ç⠺м®
- ÀçÅà ÇコÄÉ¾î ½ÃÀå, ÀûÀÀÁõº° ÁÖ¿ä Æ÷ÀÎÆ®
- ÀçÅà ÇコÄÉ¾î ½ÃÀå : ÀûÀÀÁõ µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
- ½Å°æÁúȯ ¹× Á¤½ÅÁúȯ
- ´ç´¢º´ ¹× ½ÅÀåÁúȯ
- ¾Ï
- È£Èí±âÁúȯ ¹× COPD
- ¿îµ¿ÀåÇØ
- ½ÉÇ÷°üÁúȯ ¹× °íÇ÷¾Ð
- â»ó °ü¸®
- ¸ðü Áúȯ
- ±âŸ
Á¦6Àå ÀçÅà ÇコÄÉ¾î ½ÃÀå : Áö¿ªº°, ÃßÁ¤, µ¿Ç⠺м®
- Áö¿ª Àü¸Á
- Áö¿ªº° ÀçÅà ÇコÄÉ¾î ½ÃÀå : ÁÖ¿ä ½ÃÀå ºÐ¼®
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³×´ú¶õµå
- ½º¿þµ§
- ¾ÆÀÏ·£µå
- ·¯½Ã¾Æ
- ½ºÀ§½º
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ½Ì°¡Æ÷¸£
- ű¹
- Çʸ®ÇÉ
- ¸»·¹À̽þÆ
- ´ºÁú·£µå
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« SWOT ºÐ¼®
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- ÀÌÁýÆ®
- ¿À¸¸
Á¦7Àå °æÀï ±¸µµ
- ±â¾÷ ºÐ·ù
- ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼® : °ø±Þ¾÷ü
- ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼® : ¼ºñ½º Á¦°ø¾÷ü
- Àü·« ¸ÅÇÎ
- ±â¾÷ °³¿ä : °ø±Þ¾÷ü
- B. Braun Melsungen AG
- Abbott
- Sunrise Medical
- 3M Healthcare
- Baxter International Inc.
- Medtronic PLC
- Cardinal Health Inc.
- F. Hoffmann-La Roche AG
- Air Liquide
- Amedisys, Inc.
- NxStage Medical, Inc.(Fresenius Medical Care)
- Arkray, Inc.
- Becton, Dickinson and Company
- Omron Healthcare, Inc.
- Drive DeVilbiss Healthcare
- GE Healthcare
- Medline Industries, Inc
- Koninklijke Philips NV
- Johnson & Johnson Services, Inc.
- Linde Healthcare
- Acelity(3 M)
- Vygon
- Teleflex, Inc.
- Moog Inc.
- Intersurgical Ltd.
- Fresenius Kabi AG.
- Bayer HealthCare
- GF Health Products, Inc.
LSH
¿µ¹® ¸ñÂ÷
Home Healthcare Market Growth & Trends:
The global home healthcare market size is expected to reach USD 747.70 billion by 2030, according to a report by Grand View Research, Inc., expanding at a CAGR of 10.21% from 2025 to 2030. This growth can be attributed to cost-efficiency, improved patient outcomes, and convenience offered by home healthcare agencies. In addition, the rising geriatric population and the growing prevalence of chronic diseases such as Alzheimer's, dementia, and orthopedic conditions, are expected to drive market growth. As per the Population Reference Bureau data updated in June 2019, the number of people aged 65 years and above was 52 million in 2018 and is projected to double by 2060 to reach 95 million. The World Health Organization (WHO) statistics state that there are around 50 million dementia patients in the world with 10 million new cases getting added every year. This number is expected to reach 82 million by 2030.
The establishment and maintenance of hospitals and other healthcare establishments are capital-intensive efforts. Hence, healthcare solution providers are now entering the rapidly growing market in an attempt to capitalize on the available opportunities and contain costs. Although hospital-at-home models are less prevalent in the U.S. than they are in other countries, several noteworthy initiatives have been undertaken in the past decade. These include programs at Johns Hopkins, Marshfield Clinic Health System, and Mount Sinai, which partnered with PE-backed Contessa in 2016. Moreover, these organizations engage extensively in mergers and acquisitions to expand their regional presence. Hospitals such as Apollo (Apollo Homecare) and Max (Max@Home) have entered the Indian homecare industry. Some have also established joint ventures, including the Burman family (promoters of Dabur) and UK-based Healthcare at Home, as well as India Home Healthcare and Bayada Home Healthcare, based in the U.S.
The demand for home care services is expected to increase in the immediate future, owing to the ongoing COVID-19 pandemic. These services are safer and cost-effective alternatives to hospital services. External substitutes, including hospitals, informal care, and other healthcare establishments, pose a limited threat, mostly due to their high costs. Thus, the threat of substitutes in the market is expected to be moderate during the forecast period.
Home Healthcare Market Report Highlights:
- Based on components, the service segment dominated the market with the largest revenue share of 84.1% in 2024.
- Based on indication, the neurological & mental disorder segment dominated the market with the largest revenue share of 16.75% in 2024 owing to increasing disease prevalence.
- North America home healthcare market dominated the global market with the largest revenue share of over 42.47% in 2024.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Component
- 1.2.2. Indication
- 1.3. Regional Scope
- 1.4. Estimates and Forecast Timeline
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources & Third-Party Perspectives
- 1.5.4. Primary Research
- 1.5.5. Details of Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.7.1. Commodity Flow Analysis
- 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.1.2. Approach 2: Country wise market estimation using bottom up approach
- 1.8. Data Validation & Publishing
- 1.9. Global Market: CAGR Calculation
- 1.10. List of Secondary Sources
- 1.11. List of Primary Sources
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segmental Snapshot
- 2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
- 3.1. Market Lineage
- 3.1.1. Parent Market Analysis
- 3.1.2. Ancillary Market Analysis
- 3.2. Home Healthcare Market - Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Home healthcare as a cost-effective alternative
- 3.2.1.2. Hospital solution providers penetrating the home healthcare market
- 3.2.1.3. Geographical expansion of services by providers
- 3.2.1.4. Advancement in technology
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Lower remunerations
- 3.2.2.2. Shortage of skilled healthcare staff
- 3.2.2.3. Complicated reimbursement framework and reimbursement cuts
- 3.3. Business Environmental Tools Analysis: Home Healthcare Market
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTLE Analysis
Chapter 4. Home Healthcare Market: Component Estimates & Trend Analysis
- 4.1. Home Healthcare Market, By Component Key Takeaways
- 4.2. Home Healthcare Market: Component Movement & Market Share Analysis, 2023 & 2030
- 4.3. Services
- 4.3.1. Global Home Healthcare Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.3.2. Skilled home healthcare
- 4.3.2.1. Global skilled home healthcare services market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.2. Nursing care
- 4.3.2.2.1. Global nursing care market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.3. Physician primary care
- 4.3.2.3.1. Global physician primary care market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.4. Physical/occupational/speech therapy
- 4.3.2.4.1. Global physical/occupational/speech therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.5. Hospice & palliative
- 4.3.2.5.1. Global hospice & palliative market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.6. Nutritional support & infusion therapy
- 4.3.2.6.1. Global nutritional support market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.7. Other skilled home healthcare
- 4.3.2.7.1. Global other skilled home healthcare services market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.3. Unskilled Home Healthcare
- 4.3.3.1. Global unskilled home healthcare services market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4. Equipment
- 4.4.1. Global Home Healthcare Equipment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4.2. Therapeutic
- 4.4.2.1. Global therapeutic home healthcare equipment market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2.2. Home respiratory therapy
- 4.4.2.2.1. Global home respiratory therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2.3. Home intravenous pumps
- 4.4.2.3.1. Global home IV pumps market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2.4. Home dialysis equipment
- 4.4.2.4.1. Global home dialysis equipment market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2.5. Insulin delivery
- 4.4.2.5.1. Global insulin delivery market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.2.6. Other therapeutic equipment
- 4.4.2.6.1. Global other therapeutic equipment market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3. Diagnostic
- 4.4.3.1. Global diagnostic home healthcare equipment market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.2. Diabetic care unit
- 4.4.3.2.1. Global diabetic care unit market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.3. Blood pressure monitoring
- 4.4.3.3.1. Global blood pressure monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.4. Multi parameter diagnostics monitors
- 4.4.3.4.1. Global multi parameter diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.5. Apnea and sleep monitors
- 4.4.3.5.1. Global apnea and sleep monitors market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.6. Home pregnancy and fertility kits
- 4.4.3.6.1. Global home pregnancy and fertility kits market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.7. Holter monitors
- 4.4.3.7.1. Global holter monitors market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.8. Heart rate meters
- 4.4.3.8.1. Global heart rate meter market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.3.9. Other diagnostic equipment
- 4.4.3.9.1. Global other diagnostic equipment market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.4. Mobility Assist Equipment
- 4.4.4.1. Global mobility assist equipment market estimates and forecasts, 2018 - 2030 (USD Million
- 4.4.4.2. Wheelchair
- 4.4.4.2.1. Global wheelchair market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.4.3. Home medical furniture
- 4.4.4.3.1. Global home medical furniture market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.4.4.4. Walking assist devices
- 4.4.4.4.1. Global walking assist devices market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Home Healthcare Market: Indication Estimates & Trend Analysis
- 5.1. Home Healthcare Market, By Indication: Key Takeaways
- 5.2. Home Healthcare Market: Indication Movement & Market Share Analysis, 2023 & 2030
- 5.3. Neurological & Mental Disorders
- 5.3.1. Global Neurological & Mental Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Diabetes & Kidney Disorders
- 5.4.1. Global Diabetes & Kidney Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Cancer
- 5.5.1. Global Cancer Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Respiratory Disease & COPD
- 5.6.1. Global Respiratory Disease & COPD Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Mobility Disorders
- 5.7.1. Global Mobility Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8. Cardiovascular Disorder & Hypertension
- 5.8.1. Global Cardiovascular Disorder & Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.9. Wound Care
- 5.9.1. Global Wound Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.10. Maternal Disorders
- 5.10.1. Global Maternal Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.11. Other Indications
- 5.11.1. Global Other Indications Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Home Healthcare Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Home Healthcare Market by Region: Key Marketplace Takeaway
- 6.3. North America
- 6.3.1. North America Home Healthcare Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. U.S.
- 6.3.2.1. U.S. estimated disease burden by indication, 2018 - 2022
- 6.3.2.2. Regulatory framework & reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. U.S. home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Canada
- 6.3.3.1. Canada estimated disease burden by indication, 2018 - 2022
- 6.3.3.2. Regulatory framework & reimbursement structure
- 6.3.3.3. Competitive scenario
- 6.3.3.4. Canada home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.3.4. Mexico
- 6.3.4.1. Mexico estimated disease burden by indication, 2018 - 2022
- 6.3.4.2. Regulatory framework & reimbursement structure
- 6.3.4.3. Competitive scenario
- 6.3.4.4. Mexico home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4. Europe
- 6.4.1. Europe Home Healthcare Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. UK
- 6.4.2.1. UK estimated disease burden by indication, 2018 - 2022
- 6.4.2.2. Regulatory framework & reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. UK home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Germany
- 6.4.3.1. Germany estimated disease burden by indication, 2018 - 2022
- 6.4.3.2. Regulatory framework & reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. Germany home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.4. France
- 6.4.4.1. France estimated disease burden by indication, 2018 - 2022
- 6.4.4.2. Regulatory framework & reimbursement structure
- 6.4.4.3. Competitive scenario
- 6.4.4.4. France home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.5. Italy
- 6.4.5.1. Italy estimated disease burden by indication, 2018 - 2022
- 6.4.5.2. Regulatory framework & reimbursement structure
- 6.4.5.3. Competitive scenario
- 6.4.5.4. Italy Home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.6. Spain
- 6.4.6.1. Spain estimated disease burden by indication, 2018 - 2022
- 6.4.6.2. Regulatory framework & reimbursement structure
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Spain home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.7. Netherlands
- 6.4.7.1. Netherlands estimated disease burden by indication, 2018 - 2022
- 6.4.7.2. Regulatory framework & reimbursement structure
- 6.4.7.3. Competitive scenario
- 6.4.7.4. Netherlands home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.8. Sweden
- 6.4.8.1. Sweden estimated disease burden by indication, 2018 - 2022
- 6.4.8.2. Regulatory framework & reimbursement structure
- 6.4.8.3. Competitive scenario
- 6.4.8.4. Sweden home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.9. Ireland
- 6.4.9.1. Ireland estimated disease burden by indication, 2018 - 2022
- 6.4.9.2. Regulatory framework & reimbursement structure
- 6.4.9.3. Competitive scenario
- 6.4.9.4. Ireland home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.10. Russia
- 6.4.10.1. Russia estimated disease burden by indication, 2018 - 2022
- 6.4.10.2. Regulatory framework & reimbursement structure
- 6.4.10.3. Competitive scenario
- 6.4.10.4. Russia home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.11. Switzerland
- 6.4.11.1. Switzerland estimated disease burden by indication, 2018 - 2022
- 6.4.11.2. Regulatory framework & reimbursement structure
- 6.4.11.3. Competitive scenario
- 6.4.11.4. Switzerland home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.4.12. Denmark
- 6.4.12.1. Denmark estimated disease burden by indication, 2018 - 2022
- 6.4.12.2. Regulatory framework & reimbursement structure
- 6.4.12.3. Competitive scenario
- 6.4.12.4. Denmark home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Asia Pacific Home Healthcare Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Japan
- 6.5.2.1. Japan estimated disease burden by indication, 2018 - 2022
- 6.5.2.2. Regulatory framework & reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Japan home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.3. China
- 6.5.3.1. China estimated disease burden by indication, 2018 - 2022
- 6.5.3.2. Regulatory framework & reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. China home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.4. India
- 6.5.4.1. India estimated disease burden by indication, 2018 - 2022
- 6.5.4.2. Regulatory framework & reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. India home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.5. Australia
- 6.5.5.1. Australia estimated disease burden by indication, 2018 - 2022
- 6.5.5.2. Regulatory framework & reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. Australia home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.6. South Korea
- 6.5.6.1. South Korea estimated disease burden by indication, 2018 - 2022
- 6.5.6.2. Regulatory framework & reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. South Korea home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.7. Singapore
- 6.5.7.1. Singapore estimated disease burden by indication, 2018 - 2022
- 6.5.7.2. Regulatory framework & reimbursement structure
- 6.5.7.3. Competitive scenario
- 6.5.7.4. Singapore home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.8. Thailand
- 6.5.8.1. Thailand estimated disease burden by indication, 2018 - 2022
- 6.5.8.2. Regulatory framework & reimbursement structure
- 6.5.8.3. Competitive scenario
- 6.5.8.4. Thailand home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.9. Philippines
- 6.5.9.1. Philippines estimated disease burden by indication, 2018 - 2022
- 6.5.9.2. Regulatory framework & reimbursement structure
- 6.5.9.3. Competitive scenario
- 6.5.9.4. Philippines home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.10. Malaysia
- 6.5.10.1. Malaysia estimated disease burden by indication, 2018 - 2022
- 6.5.10.2. Regulatory framework & reimbursement structure
- 6.5.10.3. Competitive scenario
- 6.5.10.4. Malaysia home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5.11. New Zealand
- 6.5.11.1. New Zealand estimated disease burden by indication, 2018 - 2022
- 6.5.11.2. Regulatory framework & reimbursement structure
- 6.5.11.3. Competitive scenario
- 6.5.11.4. New Zealand home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Latin America Home Healthcare Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Brazil
- 6.6.2.1. Brazil estimated disease burden by indication, 2018 - 2022
- 6.6.2.2. Regulatory framework & reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Brazil home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Argentina estimated disease burden by indication, 2018 - 2022
- 6.6.3.2. Regulatory framework & reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. Argentina home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7. Middle East & Africa
- 6.7.1. Middle East & Africa SWOT Analysis
- 6.7.2. Middle East & Africa Home Healthcare Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7.3. South Africa
- 6.7.3.1. South Africa estimated disease burden by indication, 2018 - 2022
- 6.7.3.2. Regulatory framework & reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. South Africa home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7.4. Saudi Arabia
- 6.7.4.1. Saudi Arabia estimated disease burden by indication, 2018 - 2022
- 6.7.4.2. Regulatory framework & reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Saudi Arabia home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7.5. UAE
- 6.7.5.1. UAE estimated disease burden by indication, 2018 - 2022
- 6.7.5.2. Regulatory framework & reimbursement structure
- 6.7.5.3. Competitive scenario
- 6.7.5.4. UAE home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7.6. Egypt
- 6.7.6.1. Egypt estimated disease burden by indication, 2018 - 2022
- 6.7.6.2. Regulatory framework & reimbursement structure
- 6.7.6.3. Competitive scenario
- 6.7.6.4. Egypt home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7.7. Oman
- 6.7.7.1. Oman estimated disease burden by indication, 2018 - 2022
- 6.7.7.2. Regulatory framework & reimbursement structure
- 6.7.7.3. Competitive scenario
- 6.7.7.4. Oman home healthcare market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Company Categorization
- 7.2. Company Market Position Analysis: Suppliers
- 7.3. Company Market Position Analysis: Service Providers
- 7.4. Strategy Mapping
- 7.5. Company Profiles: Suppliers
- 7.5.1. B. Braun Melsungen AG
- 7.5.1.1. Overview
- 7.5.1.2. Financial Performance
- 7.5.1.3. Product Benchmarking
- 7.5.1.4. Strategic Initiatives
- 7.5.2. Abbott
- 7.5.2.1. Overview
- 7.5.2.2. Financial Performance
- 7.5.2.3. Product Benchmarking
- 7.5.2.4. Strategic Initiatives
- 7.5.3. Sunrise Medical
- 7.5.3.1. Overview
- 7.5.3.2. Financial Performance
- 7.5.3.3. Product Benchmarking
- 7.5.3.4. Strategic Initiatives
- 7.5.4. 3M Healthcare
- 7.5.4.1. Overview
- 7.5.4.2. Financial Performance
- 7.5.4.3. Product Benchmarking
- 7.5.4.4. Strategic Initiatives
- 7.5.5. Baxter International Inc.
- 7.5.5.1. Overview
- 7.5.5.2. Financial Performance
- 7.5.5.3. Product Benchmarking
- 7.5.5.4. Strategic Initiatives
- 7.5.6. Medtronic PLC
- 7.5.6.1. Overview
- 7.5.6.2. Financial Performance
- 7.5.6.3. Product Benchmarking
- 7.5.6.4. Strategic Initiatives
- 7.5.7. Cardinal Health Inc.
- 7.5.7.1. Overview
- 7.5.7.2. Financial Performance
- 7.5.7.3. Product Benchmarking
- 7.5.7.4. Strategic Initiatives
- 7.5.8. F. Hoffmann-La Roche AG
- 7.5.8.1. Overview
- 7.5.8.2. Financial Performance
- 7.5.8.3. Product Benchmarking
- 7.5.8.4. Strategic Initiatives
- 7.5.9. Air Liquide
- 7.5.9.1. Overview
- 7.5.9.2. Financial Performance
- 7.5.9.3. Product Benchmarking
- 7.5.9.4. Strategic Initiatives
- 7.5.10. Amedisys, Inc.
- 7.5.10.1. Overview
- 7.5.10.2. Financial Performance
- 7.5.10.3. Product Benchmarking
- 7.5.10.4. Strategic Initiatives
- 7.5.11. NxStage Medical, Inc. (Fresenius Medical Care)
- 7.5.11.1. Overview
- 7.5.11.2. Financial Performance
- 7.5.11.3. Product Benchmarking
- 7.5.11.4. Strategic Initiatives
- 7.5.12. Arkray, Inc.
- 7.5.12.1. Overview
- 7.5.12.2. Financial Performance
- 7.5.12.3. Product Benchmarking
- 7.5.12.4. Strategic Initiatives
- 7.5.13. Becton, Dickinson and Company
- 7.5.13.1. Overview
- 7.5.13.2. Financial Performance
- 7.5.13.3. Product Benchmarking
- 7.5.13.4. Strategic Initiatives
- 7.5.14. Omron Healthcare, Inc.
- 7.5.14.1. Overview
- 7.5.14.2. Financial Performance
- 7.5.14.3. Product Benchmarking
- 7.5.14.4. Strategic Initiatives
- 7.5.15. Drive DeVilbiss Healthcare
- 7.5.15.1. Overview
- 7.5.15.2. Financial Performance
- 7.5.15.3. Product Benchmarking
- 7.5.15.4. Strategic Initiatives
- 7.5.16. GE Healthcare
- 7.5.16.1. Overview
- 7.5.16.2. Financial Performance
- 7.5.16.3. Product Benchmarking
- 7.5.16.4. Strategic Initiatives
- 7.5.17. Medline Industries, Inc
- 7.5.17.1. Overview
- 7.5.17.2. Financial Performance
- 7.5.17.3. Product Benchmarking
- 7.5.17.4. Strategic Initiatives
- 7.5.18. Koninklijke Philips N.V.
- 7.5.18.1. Overview
- 7.5.18.2. Financial Performance
- 7.5.18.3. Product Benchmarking
- 7.5.18.4. Strategic Initiatives
- 7.5.19. Johnson & Johnson Services, Inc.
- 7.5.19.1. Overview
- 7.5.19.2. Financial Performance
- 7.5.19.3. Product Benchmarking
- 7.5.19.4. Strategic Initiatives
- 7.5.20. Linde Healthcare
- 7.5.20.1. Overview
- 7.5.20.2. Financial Performance
- 7.5.20.3. Product Benchmarking
- 7.5.20.4. Strategic Initiatives
- 7.5.21. Acelity (3M)
- 7.5.21.1. Overview
- 7.5.21.2. Financial Performance
- 7.5.21.3. Product Benchmarking
- 7.5.21.4. Strategic Initiatives
- 7.5.22. Vygon
- 7.5.22.1. Overview
- 7.5.22.2. Financial Performance
- 7.5.22.3. Product Benchmarking
- 7.5.22.4. Strategic Initiatives
- 7.5.23. Teleflex, Inc.
- 7.5.23.1. Overview
- 7.5.23.2. Financial Performance
- 7.5.23.3. Product Benchmarking
- 7.5.23.4. Strategic Initiatives
- 7.5.24. Moog Inc.
- 7.5.24.1. Overview
- 7.5.24.2. Financial Performance
- 7.5.24.3. Product Benchmarking
- 7.5.24.4. Strategic Initiatives
- 7.5.25. Intersurgical Ltd.
- 7.5.25.1. Overview
- 7.5.25.2. Financial Performance
- 7.5.25.3. Product Benchmarking
- 7.5.25.4. Strategic Initiatives
- 7.5.26. Fresenius Kabi AG.
- 7.5.26.1. Overview
- 7.5.26.2. Financial Performance
- 7.5.26.3. Product Benchmarking
- 7.5.26.4. Strategic Initiatives
- 7.5.27. Bayer HealthCare
- 7.5.27.1. Overview
- 7.5.27.2. Financial Performance
- 7.5.27.3. Product Benchmarking
- 7.5.27.4. Strategic Initiatives
- 7.5.28. GF Health Products, Inc.
- 7.5.28.1. Overview
- 7.5.28.2. Financial Performance
- 7.5.28.3. Product Benchmarking
- 7.5.28.4. Strategic Initiatives
°ü·ÃÀÚ·á